Compare AbbVie Inc (ABBV) vs Strategy Inc. (MSTR) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

MSTR trades at $100.01, up 3.26% today, with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 EPS of -$24.45 versus -$2.19 expected, continuing a trend of negative profitability. Analyst consensus remains positive with a $210 price target, though fundamentals show significant challenges including a negative net income margin of -6,102.96% and substantial Bitcoin-related investment outflows.

The outlook is mixed: strong analyst support suggests upside potential, but fundamental weaknesses and persistent earnings misses pose substantial risks. Investment opportunity exists if the company can leverage its cash position for growth, while risks include continued operational losses and dependence on Bitcoin market performance.